SAN FRANCISCO, Calif., October 3, 2024 — Life Science Cares (LSC), a collective and organic effort of the Life Science industry to partner with nonprofits to disrupt the cycle of poverty and inequality, is the recipient of a generous $250,000 donation from Cytokinetics. This represents the first gift to Life Science Cares Bay Area under the new Life Science Shares program from Life Science Cares.
Cytokinetics has been a corporate partner of Life Science Cares’ Bay Area affiliate for the last three years. The partnership has engaged dozens of Cytokinetics employees in the community since its inception and helped Life Science Cares Bay Area donate close to $4 Million to deserving Bay Area nonprofit partners.
Life Science Shares is a program of Life Science Cares Inc. It provides an opportunity for individuals or companies to pledge a percentage of their earnings or lump sum contingent upon the realization of significant financial events or milestones such as capital raises, acquisitions, new indications or simply surpassing set goals.
“This program is an opportunity for companies like ours to pay forward the good fortune that we have experienced and to give back to our community in order to establish more enduring value for Life Science Cares’ investments in addressing inequities in care, gaps in education and other societal issues aligned with Life Science Cares mission.” said Robert Blum, president and CEO of Cytokinetics.
“Cytokinetics is a company now over 25 years old and as we have evolved so too has the role of the corporation in the community. Life Science Shares is a great example of what companies like ours can be doing to increase our collective impact.”
Life Science Cares provides corporations, big and small, an opportunity to engage in the community and to do so collectively. Despite turbulent and challenging economic times, Life Science companies have continued to support the effort of Life Science Cares in the community, through corporate donations, employee engagement, in kind donations and even opportunities for under-represented and under-resourced interns.
“We are grateful to Cytokinetics for their significant investment in our mission. 100% of their gift will go to support the work of deserving nonprofit partners in the Bay Area and we are thrilled about the added impact in the community this donation will facilitate. We look forward to enabling more companies to join in our mission through Life Science Shares, a new vehicle that facilitates individual and corporate giving.”, said Aisha Baro, Executive Director of Life Science Cares Bay Area.
>> Learn more about our new Life Science Shares program here
###
About Life Science Cares:
Life Science Cares is a collective effort to activate the financial and human capital of the life sciences industry – and partner with nonprofits – to disrupt the cycle of poverty and inequality in our communities. The organization helps solve societal problems through active caring, combining grants with supportive services such as volunteerism, thought leadership, and industry expertise. Since launching in Boston in 2016, the organization has generated substantial grants, gifts, education, leadership interaction, and community engagement. For more information, please visit https://lifesciencecares.org/.
About Cytokinetics:
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy which were published in the New England Journal of Medicine. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.